×
About 873 results

ALLMedicine™ Thrombin Time Center

Research & Reviews  303 results

Clinical laboratory parameters and fatality of Severe fever with thrombocytopenia syndr...
https://doi.org/10.1371/journal.pntd.0010489
PLoS Neglected Tropical Diseases; Wang Y, Song Z et. al.

Jun 18th, 2022 - Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease with high case fatality rate. Unfortunately, no vaccine or antiviral specifically targeting SFTS virus (SFTSV) are available for the time being. Our ob...

Vitamin K
https://emedicine.medscape.com/article/2088738-overview

Jun 15th, 2022 - Reference Range Vitamin K is an essential, lipid-soluble vitamin that plays a vital role in the production of coagulation proteins. The reference range of vitamin K is 0.2-3.2 ng/mL, but impaired blood clotting has been associated with levels belo...

Vitamin K
http://emedicine.medscape.com/article/2088738-overview

Jun 15th, 2022 - Reference Range Vitamin K is an essential, lipid-soluble vitamin that plays a vital role in the production of coagulation proteins. The reference range of vitamin K is 0.2-3.2 ng/mL, but impaired blood clotting has been associated with levels belo...

Vitamin K
https://emedicine.medscape.com/article/2088738-print

Jun 15th, 2022 - Vitamin K is an essential, lipid-soluble vitamin that plays a vital role in the production of coagulation proteins. The reference range of vitamin K is 0.2-3.2 ng/mL, but impaired blood clotting has been associated with levels below 0.5 ng/mL by o...

Combined Efficacy of Balloon Occlusion and Uterine Artery Embolization on Coagulation F...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159222
International Journal of Clinical Practice; Xu X, Zhu X

Jun 11th, 2022 - The present study was performed in order to investigate the conbined effect of balloon occlusion and uterine artery embolization on coagulation function in patients with high-risk placenta previa during cesarean section. There involved a total of ...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  21 results

A Trial on Prophylactic Clipping to Prevent Post-polypectomy Bleeding After Colonoscopy in Direct Oral Anticoagulant Users
https://clinicaltrials.gov/ct2/show/NCT05169242

Mar 21st, 2022 - Endoscopic resection of colonic polyps has been shown to reduce colorectal cancer-related mortality. Despite the clinical benefit of colonoscopic polypectomy, post-polypectomy bleeding (PPB) occurs in up to 6.5% of patients. Current international ...

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
https://clinicaltrials.gov/ct2/show/NCT05088928

Mar 10th, 2022 - There is an increased risk of Venous and Arterial thromboembolism in COVID-19 infection. The main reason being that the novel coronavirus SARS-CoV-2 induces hyperinflammation and subsequently immunothrombolism which is wide spread in the body. The...

Bleeding Oral Anticoagulant Analyzer (BOA)
https://clinicaltrials.gov/ct2/show/NCT05026281

Feb 14th, 2022 - This multicenter, prospective, cohort pilot study of physiopathology and physio-pharmacology, testing the added value of innovative functional exploration in addition to routine monitoring, in patients eligible for urgent reversion from anticoagul...

Application of ROTEM Technology in Aortic Surgery
https://clinicaltrials.gov/ct2/show/NCT05171023

Dec 28th, 2021 - The patient is monitored in the intensive care unit according to the following scheme: ROTEM (NATEM, INTEM, EXTEM, FIBTEM; with high clotting time (CT) values in INTEM - HEPTEM is done) and a coagulogram (activated coagulation time (ACT), activate...

Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended
https://clinicaltrials.gov/ct2/show/NCT04679298

Sep 5th, 2021 - In emergency situations such as an acute stroke or emergency surgery, information on the plasma concentration of DOAC in patients with suspected or known intake of DOAC plays a vital role in making decisions in relation to the administration of i....

see more →

News  23 results

Idarucizumab receives full FDA approval
https://www.mdedge.com/hematology-oncology/article/185007/thrombosis/idarucizumab-receives-full-fda-approval
HT Staff

Apr 19th, 2018 - Photo courtesy of Boehringer Ingelheim Dabigatran (Pradaxa) The US Food and Drug Administration (FDA) has granted full approval to idarucizumab (Praxbind®), the specific reversal agent for dabigatran etexilate mesylate (Pradaxa®). Idarucizumab rec.

Rapid Reversal of Dabigatran Anticoagulation With Idarucizumab
https://www.staging.medscape.com/viewarticle/882878

Jul 13th, 2017 - BERLIN — Using the monoclonal antibody reversal agent idarucizumab (Praxbind, Boehringer Ingelheim), researchers have shown rapid, complete, and sustained reversal of dabigatran etexilate (Pradaxa, Boehringer Ingelheim) anticoagulation in a cohort...

Idarucizumab Confirmed to Work as NOAC Reversal Agent
https://www.medpagetoday.com/cardiology/prevention/66557

Jul 11th, 2017 - Action Points Note that this cohort study evaluating the use of idarucizumab for the reversal of dabigatran demonstrated prompt efficacy at reducing life-threatening bleeding and restoring coagulation parameters. Be aware this study lacked a conte...

Idarucizumab reversed dabigatran completely and rapidly in study
https://www.mdedge.com/neurology/article/142140/thrombosis/idarucizumab-reversed-dabigatran-completely-and-rapidly-study
Amy Karon

Jul 11th, 2017 - One IV 5-g dose of idarucizumab completely, rapidly, and safely reversed the anticoagulant effect of dabigatran, according to final results for 503 patients in the multicenter, prospective, open-label, uncontrolled RE-VERSE AD study. Uncontrolled.

Idarucizumab reversed dabigatran completely and rapidly in study
https://www.mdedge.com/anticoagulationhub/article/142140/thrombosis/idarucizumab-reversed-dabigatran-completely-and-rapidly
Amy Karon

Jul 11th, 2017 - One IV 5-g dose of idarucizumab completely, rapidly, and safely reversed the anticoagulant effect of dabigatran, according to final results for 503 patients in the multicenter, prospective, open-label, uncontrolled RE-VERSE AD study. Uncontrolled.

see more →